Suchergebnisse - "Jenner, Matthew W."

PubPharm (43)

1

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Kaiser, M. | Hall, A. | Walker, K. | +17

2

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

enthalten in: EClinicalMedicine | 2023

von Jones, J. | Cairns, D. | Menzies, T. | +15

3

Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma : results from the Myeloma UK (MUK) nine OPTIMUM trial

enthalten in: British journal of haematology | 2023

von Faustini, S. | Hall, A. | Brown, S. | +12

4

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages : results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

enthalten in: British journal of haematology | 2023

von Jenner, M. | Pawlyn, C. | Davies, F. | +16

5

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages : results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial

enthalten in: British Journal of Haematology | 2023

von Jenner, M. | Pawlyn, C. | Davies, F. | +15

6

Immune responses to COVID‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma : results from the Myeloma UK ( MUK) nine OPTIMUM trial

enthalten in: British Journal of Haematology | 2023

von Faustini, S. | Hall, A. | Brown, S. | +11

7

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma : Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von de Tute, R. | Pawlyn, C. | Cairns, D. | +14

CommentIn: J Clin Oncol. 2022 Sep 1;40(25):2863-2866. - PMID 35772041

8

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

enthalten in: Haematologica | 2021

von Jackson, G. | Davies, F. | Pawlyn, C. | +21

9

Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial

enthalten in: Leukemia | 2021

von Croft, J. | Ellis, S. | Sherborne, A. | +19

10

Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma : a multicenter real world UK experience

enthalten in: Leukemia & lymphoma | 2021

von Maouche, N. | Kishore, B. | Jenner, M. | +14

1
2
3
4
5
Nächster »
[5]